Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for depressed smokers: therapy plus quit support shows promise

NCT ID NCT00494728

Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a special type of talk therapy (CBASP) to standard smoking cessation treatment helps depressed smokers quit and feel better. About 91 adults with depression who smoked at least 5 cigarettes a day took part. The goal was to see if the combined approach improves quit rates and reduces depressive symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

91 people

The number who actually took part.

Started

Jun 2007

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Currently meeting DSM-IV criteria for major depressive disorder, recurrent; or major depressive disorder, recurrent, in partial remission; or major depressive disorder, single episode with a duration of 2 years or more; or; dysthymic disorder. 2. Score greater than or equal to 8 on the PHQ at baseline 3. Age greater than or equal to 16 4. Smoking greater than or equal to 5 cigarettes per day 5. Willing to set a quit date within 6 weeks of baseline 6. English speaking and have a telephone 7. Willing to attend all sessions 8. Willing to provide informed consent and agree to all assessments and study procedures Exclusion Criteria: 1. History of psychotic or bipolar disorder 2. Current psychotherapy 3. Current use of antidepressant 4. Current principal DSM-IV Axis I disorder other than unipolar depression or nicotine dependence 5. Involvement in any smoking cessation activities 6. Current use of nicotine replacement therapy 7. Known health or other complications that would adversely affect attendance 8. Severe levels of depressive symptoms, vegetative symptoms, and/or symptoms related to secondary psychiatric disorders that place participant at risk for harm or require immediate treatment 9. Currently at severe or extreme risk of suicide or moderate risk with resolved plans and preparation 10. Medical contraindications for use of nicotine patch, including uncontrolled heart disease, history of severe hypersensitivity to nicotine replacement products, or currently pregnant or lactating 11. 11\) History of current medical condition, or any other factor that, in the judgment of the principal investigator, would likely preclude completion of study requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression depressive disorder dysthymic disorder major depressive disorder nicotine dependence Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression Smoking

Contacts and locations

Locations

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.